Hypertension | Losartan in Hypertensive Men and Women With Sleep Apnea Before and on Continuous Positive Airway Pressure (CPAP) Treatment
Hypertension research study
What is the primary objective of this study?
Obstructive sleep apnea (OSA) is a highly prevalent condition in hypertensive patients. The renin-angiotension-aldosterone-system (RAAS) has a central role in blood pressure control. An angiotensin-II-antagonist, Losartan, is an effective antihypertensive drug. However, some patients respond to this drug worse than the others, and it is a clinical praxis to either increase the dosage and/or add another drug. There is limited data regarding the impact of antihypertensive drugs in OSA patients, i.e., whether or not OSA may constitute the subgroup of therapy-resistent hypertensive patients. In the literature, there is no data, either, whether or not CPAP treatment may have an additive blood pressure lowering impact in this certain subgroup.
Who is eligible to participate?
Inclusion Criteria: - Body Mass Index <35 kg/m2 - Systolic Blood Pressure >=140 mmHg and/or Diastolic Blood Pressure >=95 mmHg - No known clinical disease except hypertension - No cardiovascular medication - Apnea-Hypopnea Index < 5/h (no OSA), or Apnea Hypopnea Index >=15/h (OSA) Exclusion Criteria: - Manifest diabetes, liver- or kidney disease Signs of atrial fibrillation or former myocardial infarction at electrocardiogram
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:LosartanLosartan 50 mg daily during 6 + 6 weeks
Other:CPAPCPAP during the second 6 week-period
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
1Hypertensive Men and Women Without OSA on Losartan (n=30)
2Hypertensive Men and Women With OSA on Losartan (n=30)
3Hypertensive Men and Women with OSA on Losartan and CPAP (n=30)
Start Date: June 2008
Completed Date: February 2014
Phase: Phase 4
Primary Outcome: 24 h blood pressure (mean blood pressure; mmHg)
Secondary Outcome: Markers of sympathetic activity, RAAS-activity, cardiovascular biomarkers
Study sponsors, principal investigator, and references
Principal Investigator: Yuksel Peker, Assoc. Prof.
Lead Sponsor: Skaraborg Hospital
Collaborator: Göteborg University